Published in Immunotherapy Weekly, June 22nd, 1998
Researcher W.J. Britton and colleagues from Australia's Centenary Institute of Cancer Medicine and Cell Biology found that the peptide has neutrophil and macrophage stimulatory properties without the adverse effects associated with tumor necrosis factor (TNF) administration.
The control of mycobacterial infections depends on the cytokine-mediated activation of mononuclear phagocytes to inhibit the growth of intracellular mycobacteria. Optimal activation requires the presence of T-cell-derived gamma...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly